Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1)
AssigneeThe Schepens Eye Research Institute, Inc.
InventorsDong Feng Chen, Chenying Guo
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of promoting neuronal growth by administering IGFBPL-1, or an agent that increases or stabilizes IGFBPL-1 activity to a subject in need thereof, e.g., a subject in need of treating optic nerve degeneration.
Claims12
A method of reducing severity of glaucoma in a subject in need thereof, the method comprising intravitreally administering to the subject a composition comprising an insulin-like growth factor binding protein-like 1 (IGFBPL-1) protein.
A method of reducing severity of a neuronal injury in a subject in need thereof, the method comprising intravitreally administering to the subject a composition comprising an IGFBPL-1 protein, wherein the subject has glaucoma.
Dependencies are inferred from the claim text.